Page 242 - Essential Haematology
P. 242

228  /  Chapter 17  Acute lymphoblastic leukaemia



                     AML1  translocation. The AML1 protein plays an   nosis. Translocations of chromosome 11q23 involve
                    important part in transcriptional control of haemo-  the  MLL  gene and are seen particularly in cases of
                    poiesis and is repressed by the TEL - AML1 fusion   infant leukaemia. Using more sensitive molecular
                    protein.                                  genetic tests, as well as fl uorescence  in situ  hydridi-

                       The frequency of the Philadelphia translocation   zation (FISH) analysis, some cases normal by
                    t(9; 22) increases with age and carries a poor prog-  conventional cytogenetic testing are found to
                                                              have fusion genes, e.g BCR - ABL1 or other genetic
                                                              abnormalities. These molecular genetic changes


                         Table 17.3   Immunological markers for   carry prognostic significance whether or not a cor-

                     classifi cation of acute lymphoblastic (ALL)   responding chromosomal change is present.
                     leukaemia.                                  T - ALL accounts for 15% of childhood and 25%
                                                              of adult ALL and the clinical picture is often domi-
                                           ALL                      nated by a very high white cell count, mediastinal
                         Marker        B                   T

                                                              mass or pleural effusion. TCR (and in 20% the  IGH
                           B lineage                          gene) show clonal rearrangement. Cytogenetic
                         CD19              +                 −       changes often involve the TCR loci with diff erent

                         cCD22             +                 −       partner genes. The majority of cases have acquired
                         cCD79a            +                 −       genetic abnormalities that lead to constitutive acti-
                         CD10              +  or  −          −       vation of the  NOTCH  signalling pathway and drugs
                         cIg               +  (pre - B)       −       that target these abnormalities are being developed
                         sIg               −                 −       (Fig.  17.5 ).
                         TdT               +                 +
                           T lineage
                                                                  Treatment
                         CD7               −                 +

                         cCD3              −                 +        This may be conveniently divided into  supportive
                         CD2               −                 +       and  specifi c  treatment.
                         TdT               +                 +
                                                                  General  s upportive  t herapy
                           c, Cytoplasmic; S, surface.

                           *   B - ALL resembles precursor B - ALL immunologically but     General supportive therapy for bone marrow failure
                     has surface immunoglobulin (Ig) and is terminal
                                                  −

                     deoxynucleotidyl transferase negative (TdT ).       is described in Chapter  12    and includes the inser-
                                                              tion of a central venous cannula, blood product
                                       Infants            Children            Adults











                                     Ph/BCR-ABL1  Hyperdiploidy  TEL-AML1  11q23/MLL  Others



                              Figure 17.4   Cytogenetic subsets of acute lymphoblastic leukaemia (ALL). The incidence of different cytogenic


                    abnormalities in infants, children and adults.
   237   238   239   240   241   242   243   244   245   246   247